万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://academic.oup.com/icvts
3、投稿网址：
https://www.editorialmanager.com/icvts/default.aspx
4、官网邮箱：info@ejcts.org（编辑部）
5、官网电话：+49-761-27090860（编辑部）
6、期刊刊期：月刊，一年出版12期。
2021年7月15日星期四
投稿须知【官网信息】
Author Guidelines
Interactive CardioVascular and Thoracic Surgery (ICVTS) welcomes scientific contributions in the field of cardiovascular and thoracic surgery, including minimally invasive techniques, percutaneous interventions, catheter-based valve operations and perioperative care.
Various article types are available: Best Evidence Topics, Brief Communications, Case Reports, Original Articles, Meta-Analyses, State-of-the-Art, Videos, Work in Progress Reports.
All manuscripts are subject to review by the Editor-in-Chief, Associate Editors, Invited Reviewers and a Statistician when appropriate. Acceptance is based on the originality, significance, and validity of the material presented. This page outlines instructions for submitting your manuscript to ICVTS. The journal is published monthly online-only. For information on journal policies, please visit our policies page.
Transition to Open Access
In order to expand the visibility of the groundbreaking research published in ICVTS and grow the journal’s benefit to our community, Interactive CardioVascular and Thoracic Surgery is transitioning to fully open access from 2 August 2021. As a fully open access journal all articles will be published in the journal under an open access licence immediately upon publication. You will need to pay an open access charge to publish under an open access licence.*
Details of the open access licences and open access charges.
If the corresponding author is based in one of the countries included in our Developing Countries Initiative, your article will be eligible for a full waiver or discounted open access charge.
OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution is participating.
Please note that you may be eligible for a discount to the open access charge based on society (EACTS) membership. Authors may be asked to prove eligibility for the member discount.
*manuscripts submitted before 2 August 2021, but accepted and published after ICVTS changes to an open access journal, will also be published under an open access licence, but the open access charge will be waived by default for manuscripts in that situation.
*papers published on Advance Access before 2 August 2021 under a standard licence will publish into issues under the terms of the original licence as signed. As such, issues of the Journal published from 2 August 2021 until the end of 2021 may contain both Open Access and standard licence content. Articles published under a standard licence will be ‘free to view’.
The APCs are:
Original/Review article
from 2 Aug 2021
£ $ €
ICVTS (EACTS member) 1260 1714 1399
ICVTS (EACTS non-member 1800 2448 1998
Case Reports/Brief Communications
from 2 Aug 2021
£ $ €
ICVTS (EACTS member) 455 591 505
ICVTS (EACTS non-member 650 884 722
Editorial Office
Editorial Office
Interactive CardioVascular and Thoracic Surgery
University Freiburg - Medical Center
Department of Cardiovascular Surgery
Hugstetter Str. 55
79106 Freiburg
Germany
Tel: +49-761-27090860
E-mail:info@icvts.org
Submission
All material to be considered for publication in Interactive CardioVascular and Thoracic Surgery should be submitted electronically via the journal's online submission system.
Cover letter
All new manuscripts should be accompanied by a cover letter (to be filled in online) and include the following statements:
The manuscript has not previously been published in print or electronic form and is not under consideration by another publication (see Interact CardioVasc Thorac Surg 2015).
All authors have contributed significantly to the content of the article - see authorship criteria below.
All authors have read and approve the submission of the manuscript to ICVTS.
Subject to acceptance, authors will sign an exclusive licence to publish.
There is no ethical problem or undeclared conflict of interest (see below) For publication ethics, experimental ethics on human subjects and animals, etc. see our policies page, and ensure that the article adheres to the journal requirements.
Revised manuscripts
When submitting revised manuscripts, label the files accordingly (2nd version, 3rd version, etc.). Respond to all points raised by the Editors, Reviewers and Statistician in the ‘Respond to Reviewers’ field in the Metadata, outlining any changes that have been made. All changes should be marked in red in the revised manuscript to facilitate editorial reassessment.
Authorship
To be listed as an author the journal expects each author to meet the following criteria recommended by the International Committee of Medical Journal Editors (ICMJE):
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
Drafting the work or revising it critically for important intellectual content; AND
Final approval of the version to be published; AND
Agreement to be accountable for his/her contributions of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved (modified from the original ICMJE criteria).
All authors must confirm their affiliation and contribution to an article by responding to the authorship verification email that is sent to them from the online submission system.
No authors can be removed after submission of the revised version without the written authorization from all authors and approval by the Editorial Office.
Redundant (Duplicate) Submission
It is recommended that Authors read the updated version of the statement on redundant submission, jointly published with other journals in 2015.
Statistical and Data Reporting Guidelines
It is highly recommended that Authors consult the guidelines on Statistical and data reporting; see also the corrigendum.
Raw Data
The full set of raw data must be made readily available upon the request of reviewers or editors during the review process and/or after publication.
Availability of Data and Materials
Where ethically feasible, we strongly encourage authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. Information on general repositories for all data types, and a list of recommended repositories by subject area, are available on the Research Data Policy page.
Data Availability Statement
Authors are required to include a Data Availability Statement to their manuscript file. The statement will be included in the published article.
More information and example Data Availability statements.
Data Citation
We support the Force 11 Data Citation Principles and require that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI).
Data citations should include the minimum information recommended by DataCite:
[dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier
*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list.
Clinical Trials
Registering Clinical Trials
In accordance with the Clinical Trial Registration Statement from the ICMJE all clinical trials published in the journal must be registered in a WHO-approved public trials registry or in ClinicalTrials.gov at or before the onset of participant enrolment. For any clinical trials commencing prior to 1 July 2005, retrospective registration will be accepted.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, managed by a not-for-profit organization, and include all the necessary information as specified by the ICMJE. Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (<500 words or less) or a table. Authors are requested to provide the exact URL and unique identification number for the trial registration at the time of submission on the manuscript’s title page. This information will be included in the published article.
Reporting Clinical Trials
Clinical trials should comply with the Consolidated Standards of Reporting Trials Statement (CONSORT), which is available here. Authors reporting on randomized clinical trials (RCTs) should consult the CONSORT checklist when preparing their manuscript. All RCT data will be evaluated in accordance with the rules and checklist of the CONSORT statement.
Other types of studies should follow guidelines where available. These include:
STARD (Standards for the Reporting of Diagnostic accuracy studies)
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)
PRISMA (Transparent Reporting of Systematic Reviews and Meta-Analyses)
MOOSE (Meta-analyses of observational studies)
For further information on good reporting of health research studies please go to the EQUATOR network. The relevant checklist should be duly filled in and uploaded as ‘Prisma/Consort checklist’.
Language Editing Pre-Submission
If your first language is not English, we recommend that you consult an English language editing service to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication. For further information on this service, please visit the language services webpage.
……
更多详情：
https://academic.oup.com/icvts/pages/Submission_Online
